ATRA
Atara Biotherapeutics Inc
8.90$
+4.1%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 62.9% | 61.6% | 64.4% | 53.2% | 64.4% | 59.5% | 43.8% | 67.1% | 61.1% | 60.4% | 60.9% | 64.4% | |
| 34.3% | 15.6% | 21.2% | 26.7% | 32.6% | 22.9% | 22.3% | 45.8% | 19.0% | 41.9% | 41.8% | 15.3% | |
| 54.2% | 31.3% | 28.0% | 30.1% | 47.1% | 39.0% | 22.3% | 60.5% | 45.5% | 41.9% | 41.8% | 47.0% | |
| 0.1% | 20.6% | 21.7% | 2.1% | 0.9% | 1.4% | 14.3% | 0.0% | 6.3% | 6.2% | 0.0% | 1.5% | |
| 3.5% | 5.9% | 9.7% | 16.0% | 9.8% | 9.8% | 0.0% | 0.0% | 0.0% | 0.0% | – | – | |
| 33.8% | – | – | – | – | – | – | – | – | – | – | – | |
| 126.9% | 160.0% | 159.5% | 194.5% | 163.4% | 189.2% | 188.8% | 195.0% | 221.4% | 290.3% | 286.6% | 276.0% | |
| 41.9% | 85.9% | 109.3% | 126.4% | 109.3% | 123.4% | 77.2% | 39.5% | 59.9% | 73.7% | 28.2% | 32.6% | |
| 7.0% | 7.4% | 8.5% | 11.9% | 10.3% | 12.8% | 22.4% | 6.1% | 38.5% | 53.3% | 5.1% | 5.2% | |
| 3.4% | 2.2% | 1.7% | 4.5% | 1.5% | 4.0% | 2.2% | 4.8% | 1.1% | 0.6% | 3.2% | 3.9% | |
| -26.9% | -60.0% | -59.5% | -94.5% | -63.4% | -89.2% | -88.8% | -95.0% | -121.4% | -190.3% | -186.6% | -176.0% | |
| -1,011.0% | -1,189.8% | -1,210.7% | -1,722.3% | -1,430.8% | -1,883.2% | -3,250.5% | -5,458.1% | -6,691.0% | -9,991.9% | -10,131.6% | -9,659.6% | |
| 2.3% | 2.6% | 3.4% | 5.2% | 5.2% | 9.8% | 17.5% | 33.4% | 45.0% | 62.9% | 70.4% | 71.5% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.